Servier Bio-Innovation
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Servier Bio-Innovation sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).
Servier Bio-Innovation: 9 sponsored US clinical trials, 3 recruiting.
Servier Bio-Innovation sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 1 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is MSI-H/dMMR Gastroesophageal-junction Cancer, with 1 trials.
Top-decile sponsor footprint
Servier Bio-Innovation ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
9 total, page 1 of 1
A Study of an IDH1m Inhibitor in Participants With IDH1-Mutated Malignancies and Hepatic or Renal Impairment
NCT07006688
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
NCT06127407
S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP
NCT06188702
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
NCT06116136
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
NCT06162572
A Study to Evaluate S227928 as a Single Agent and in Combination With Venetoclax in Patients With R/R AML, MDS/AML, or CMML
NCT06563804
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
NCT05921760
A Phase 1, Open-Label Study to Evaluate the Effect of a Low-Fat Meal and Multiple Doses of Ciprofloxacin on the Pharmacokinetics of Vorasidenib in Healthy Subjects
NCT05843708
A Study of PRS-344/S095012 (PD-L1x4-1BB Bispecific Antibody) in Patients With Solid Tumors
NCT05159388
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 3 | 1 |
Therapeutic Areas
What is open in the Servier Bio-Innovation pipeline
3 recruiting of 9 indexed (33% open); 1 completed (11%).
Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: MSI-H/dMMR Gastroesophageal-junction Cancer (1 trial), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Servier Bio-Innovation: open-pipeline peers nationwide
Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Servier Bio-Innovation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 9 trials (± recruiting share)
- 4D Molecular Therapeutics · 9 trials · 44% recruiting
- 9 Meters Biopharma · 9 trials · 0% recruiting
- Aadi Bioscience · 9 trials · 33% recruiting
- Ablynx, a Sanofi company · 9 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
- Adagio Medical · 33% recruiting · 3 trials
Related
What to do with this Servier Bio-Innovation page
9 registered trials is a research-attention snapshot, not an endorsement of Servier Bio-Innovation or any single study.
- 3 of Servier Bio-Innovation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- MSI-H/dMMR Gastroesophageal-junction Cancer is the condition Servier Bio-Innovation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See MSI-H/dMMR Gastroesophageal-junction Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Servier Bio-Innovation pipeline card: 9 registered trials from official public datasets.Report a data error.